A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)
Status:
Completed
Trial end date:
2013-03-07
Target enrollment:
Participant gender:
Summary
This study will investigate and compare the pharmacokinetics of a single 25-mg dose of
MK-3102 in participants with moderate hepatic impairment and matched healthy participants.
The primary hypothesis is that in participants with moderately impaired hepatic function, the
area under the concentration-time curve from time zero to infinity (AUC0-∞) is similar to
that observed in healthy matched control participants following a single 25 mg oral dose of
MK-3102. Specifically, the true ratio (moderately impaired hepatic function patients/healthy
matched control subjects) of geometric means for AUC0-∞ is no greater than 2.